What is the recommended outpatient management of herpes zoster (shingles) in an otherwise healthy adult, including antiviral regimen, pain control, steroid use, and post‑episode vaccination?

Outpatient Management of Herpes Zoster (Shingles)

Antiviral Therapy

Start oral antiviral therapy immediately—ideally within 72 hours of rash onset—with valacyclovir 1000 mg three times daily for 7–10 days, continuing until all lesions have completely scabbed. 1

First-Line Oral Antiviral Options

• Valacyclovir 1000 mg three times daily for 7–10 days offers superior bioavailability and less frequent dosing than acyclovir, potentially improving adherence and pain reduction 1, 2
• Acyclovir 800 mg five times daily for 7–10 days remains effective but requires more frequent dosing 1, 2
• Famciclovir 500 mg three times daily for 7 days provides comparable efficacy with better bioavailability 1, 2

Critical Treatment Principles

• Continue antiviral therapy until all lesions have scabbed—this is the key clinical endpoint, not an arbitrary 7-day duration 1
• Treatment initiated after 72 hours may still provide benefit, particularly for reducing postherpetic neuralgia risk 2
• Never use topical antivirals—they are substantially less effective than systemic therapy 1

When to Escalate to Intravenous Acyclovir

Switch to IV acyclovir 10 mg/kg every 8 hours if any of the following are present: 1

• Disseminated disease (≥3 dermatomes, visceral involvement, or hemorrhagic lesions)
• Facial or ophthalmic involvement with cranial nerve risk
• CNS complications (encephalitis, meningitis, Guillain-Barré syndrome)
• Severe immunosuppression
• Lack of improvement after 7–10 days of oral therapy (suspect acyclovir resistance)

---

Pain Management

Acute Pain Control

• Over-the-counter analgesics (acetaminophen, ibuprofen) for mild-to-moderate pain 1
• Gabapentin is the first-line agent for acute neuropathic pain, titrated up to 2400 mg daily in divided doses 1
• Topical ice or cold packs can reduce pain and swelling during the acute phase 1

Adjunctive Neuropathic Pain Therapies

• Pregabalin may be added if gabapentin alone is insufficient 1
• Tricyclic antidepressants (e.g., amitriptyline) can help control neuropathic pain, though somnolence occurs in ~80% of patients 1
• Topical capsaicin 8% patch (single application) or lidocaine patches for localized pain 1, 3

Postherpetic Neuralgia (PHN) Prevention

Early antiviral treatment within 72 hours significantly reduces the risk of PHN, which occurs in approximately 20% of patients and is defined as pain persisting ≥90 days after rash onset 2, 4

---

Corticosteroid Use

Oral prednisone may be considered as adjunctive therapy in select cases of severe, widespread shingles, but carries significant risks—particularly in elderly patients—and should generally be avoided in immunocompromised patients. 1

When to Consider Corticosteroids

• Ramsay Hunt syndrome (facial nerve involvement): prednisone 60 mg daily combined with antivirals, started within 72 hours 1
• Severe, widespread disease in otherwise healthy adults 1

Absolute Contraindications

• Immunocompromised patients (increased risk of disseminated infection) 1
• Poorly controlled diabetes, steroid-induced psychosis history, severe osteoporosis 1

Important Caveat

Never apply topical corticosteroids to active shingles lesions—this can worsen infection and increase dissemination risk, particularly in immunocompromised patients 1

---

Infection Control & Monitoring

Transmission Precautions

• Avoid contact with susceptible individuals (pregnant women, immunocompromised persons, those without chickenpox history) until all lesions have crusted 1
• Cover lesions with clothing or dressings to minimize transmission risk 1
• Lesions are contagious via direct contact or aerosolized vesicular fluid 1

Monitoring During Treatment

• Baseline renal function before starting oral antivirals; dose adjustments mandatory for creatinine clearance <50 mL/min 1
• Ensure adequate hydration to reduce crystalluria risk (occurs in up to 20% of patients) 1
• For IV acyclovir: monitor renal function weekly and watch for thrombotic thrombocytopenic purpura/hemolytic uremic syndrome 1

---

Post-Episode Vaccination

Administer the recombinant zoster vaccine (Shingrix) ≥2 months after complete resolution of acute symptoms to prevent future episodes. 1, 5, 6

Vaccination Schedule

• Two-dose series: second dose given 2–6 months after the first (minimum 4-week interval) 5
• For immunocompromised adults ≥18 years: shortened schedule with second dose at 1–2 months 5

Rationale for Post-Zoster Vaccination

• Having shingles once does not provide reliable protection against recurrence 5, 6
• 10-year cumulative recurrence risk is 10.3% 5, 6
• Shingrix demonstrates >90% efficacy in preventing future episodes across all age groups ≥50 years 5

Key Points

• Never use live-attenuated Zostavax in immunocompromised patients—only Shingrix is appropriate 5, 6
• Vaccination is recommended regardless of prior shingles history 5
• No maximum interval after a shingles episode; vaccinate once acute symptoms resolve 6

---

Special Populations & Pitfalls

Immunocompromised Patients

• Consider temporary reduction in immunosuppressive medications for disseminated or invasive disease 1
• May require extended antiviral treatment beyond 7–10 days as lesions develop over longer periods 1
• Higher risk for acyclovir resistance (up to 7% vs. rare in immunocompetent patients) 1

Treatment Failure & Resistance

• Suspect acyclovir resistance if lesions have not begun resolving within 7–10 days 1
• Obtain viral culture with susceptibility testing 1
• For confirmed resistance: foscarnet 40 mg/kg IV every 8 hours until clinical resolution 1

Common Pitfalls to Avoid

• Do not stop antivirals at exactly 7 days if lesions are still forming or have not scabbed 1
• Do not delay treatment waiting for the "72-hour window"—start immediately upon diagnosis 1, 2
• Do not confuse short-course HSV regimens (1–3 days) with VZV treatment—these are inadequate for shingles 1